Research
Hormonal
Tirzepatide improves cardiovascular risk factors, including lipid profiles and blood pressure, without increasing cardiovascular event risk in T2DM patients.
Beyond weight loss, Tirzepatide improves heart health markers by lowering bad fats (triglycerides, LDL) and raising good fats (HDL), while also lowering blood pressure. It does not appear to increase heart attack or stroke risk in T2DM patients.
GoodSupportsHIGH confidence
Tirzepatide shows positive effects on a variety of cardiovascular risk factors... demonstrated greater and clinically meaningful HbA1c and did not increase any cardiovascular risk
Why this rating
Based on Phase 3 trials and meta-analysis; CVOT results still pending.
Source
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Palak Dutta et al. · Cureus · 2023
DOI 10.7759/cureus.38379
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →